Cadrenal Therapeutics, Inc. Common Stock (CVKD) NASDAQ
4.19
-0.16(-3.68%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.19
-0.16(-3.68%)
Currency In USD
Address
822 A1A North
Ponte Vedra, FL 32082
United States of America (the)
Phone
904 300 0701
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
January 20, 2023
| Name | Title | Pay | Year Born |
| Quang X. Pham | Chairman & Chief Executive Officer | 1.06M | 1965 |
| Jeffrey Cole | Chief Operating Officer | 615,361 | 1968 |
| James J. Ferguson FACC | Chief Medical Officer | 616,889 | 1954 |
| Matthew K. Szot | Co-Founder & Chief Financial Officer | 654,969 | 1974 |
| Matthew Boxer | Executive Vice President of Corporate Development | 0 | N/A |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.